1. Harder, B.C., et al. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol 155, 1119-1124. e1111 (2013).
2. Kent, D., Pennie, F., Laws, D., White, S. & Clark, D. The influence of retinopathy of prematurity on ocular growth. Eye 14, 23-29 (2000).
3. McLoone, E.M., O’Keefe, M., McLoone, S.F. & Lanigan, B.M. Long-term refractive and biometric outcomes following diode laser therapy for retinopathy of prematurity. J AAPOS 10, 454-459 (2006).
4. Sayman Muslubas, I., Karacorlu, M., Hocaoglu, M., Arf, S. & Ozdemir, H. Retinal and choroidal thickness in children with a history of retinopathy of prematurity and transscleral diode laser treatment. Eur J Ophthalmol 27, 190-195 (2017).
5. Yang, C., Wang, A., Shih, Y. & Hsu, W. Astigmatism and biometric optic components of diode laser-treated threshold retinopathy of prematurity at 9 years of age. Eye 27, 374-381 (2013).
6. Liang, J. Systematic review and meta-analysis of the negative outcomes of retinopathy of prematurity treated with laser photocoagulation. Eur J Ophthalmol 29, 223-228 (2019).
7. Ruan, L., Shan, H.-D., Liu, X.-Z. & Huang, X. Refractive status of Chinese with laser-treated retinopathy of prematurity. Optom Vis Sci 92, S3 (2015).
8. Lee, Y.-S., et al. Macular structures, optical components, and visual acuity in preschool children after intravitreal bevacizumab or laser treatment. Am J Ophthalmol 192, 20-30 (2018).
9. Connolly, B.P., et al. A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 2. Refractive outcome. Ophthalmology 109, 936-941 (2002).
10. Inoue, T., et al. Does the number of laser applications for ROP treatment influence the degree of myopia? Graefes Arch Clin Exp Ophthalmol, 1-6 (2020).
11. Geloneck, M.M., et al. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol 132, 1327-1333 (2014).
12. Group, E.T.f.R.o.P.C. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121, 1684 (2003).
13. Gordon, R.A. & Donzis, P.B. Refractive development of the human eye. Arch Ophthalmol 103, 785-789 (1985).
14. Baayen, R.H., Davidson, D.J. & Bates, D.M. Mixed-effects modeling with crossed random effects for subjects and items. Journal of Memory and Language 59, 390-412 (2008).
15. Bates, D., Mächler, M., Bolker, B. & Walker, S. Fitting Linear Mixed-Effects Models Usinglme4. Journal of Statistical Software 67(2015).
16. Burnham, K.P. & Anderson, D.R. Multimodel inference: understanding AIC and BIC in model selection. Sociol Methods Res 33, 261-304 (2004).
17. Johnson, D.H. The Insignificance of Statistical Significance Testing. J Wildl Manage 63, 763-772 (1999).
18. Algawi, K., Goggin, M. & O'Keefe, M. Refractive outcome following diode laser versus cryotherapy for eyes with retinopathy of prematurity. Br J Ophthalmol 78, 612-614 (1994).
19. Knight-Nanan, D.M. & O'Keefe, M. Refractive outcome in eyes with retinopathy of prematurity treated with cryotherapy or diode laser: 3 year follow up. Br J Ophthalmol 80, 998-1001 (1996).
20. Yoon, J.M., et al. Outcomes after laser versus combined laser and bevacizumab treatment for type 1 retinopathy of prematurity in zone I. Retina 37, 88-96 (2017).
21. Hwang, C.K., Hubbard, G.B., Hutchinson, A.K. & Lambert, S.R. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology 122, 1008-1015 (2015).
22. VanderVeen, D.K., et al. Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: a report by the American Academy of Ophthalmology. Ophthalmology 124, 619-633 (2017).
23. Mintz-Hittner, H.A., Kennedy, K.A. & Chuang, A.Z. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364, 603-615 (2011).